NEUE · As filed with the SEC
NeueHealth cash flow statement, by fiscal year
The statement as NeueHealth presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | — | — | — | (1,184,862) |
| Net loss | — | — | (1,359,880) | — |
| Net loss | (99,717) | (1,265,808) | — | — |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||
| Depreciation and amortization | — | — | 50,575 | — |
| Impairment of intangible assets | — | — | 49,331 | — |
| Impairment of goodwill | — | — | 75,372 | — |
| Depreciation and amortization | 15,646 | 24,167 | — | 35,484 |
| Impairment of intangible assets | — | 0 | — | — |
| Intangible assets impairment | 11,411 | — | — | — |
| Impairment of goodwill | 0 | 587,535 | — | — |
| Share-based compensation | 70,207 | 83,692 | 109,713 | 68,423 |
| Deferred income taxes | — | — | 2,027 | (25,654) |
| Payment-In-Kind (“PIK”) Interest | 17,005 | — | — | — |
| Deferred income taxes | 0 | (3,063) | — | — |
| Unrealized loss (gain) on equity securities | — | 0 | 55,449 | (80,231) |
| Investment impairment | — | 0 | 67,723 | — |
| Warrant expense | — | 13,971 | — | — |
| Gain on troubled debt restructuring | (30,311) | — | — | — |
| Net accretion of investments | (229) | (17,986) | — | — |
| Loss on disposal of property, equipment, and capitalized software | 709 | 6,418 | — | — |
| Gain on sale of California MA business | (65,210) | — | — | — |
| Other, net | 5,135 | 1,858 | 24,163 | 20,254 |
| Changes in assets and liabilities, net of acquired assets and liabilities: | ||||
| Accounts receivable | (2,001) | (7,756) | 28,787 | (32,941) |
| Direct Contracting performance year receivable | — | — | (99,181) | — |
| ACO REACH performance year receivable | 20,803 | (16,697) | — | — |
| Other assets | (10,162) | 191,441 | (21,832) | (143,463) |
| Medical cost payable | (55,254) | (635,616) | 279,563 | 475,461 |
| Risk adjustment payable | — | — | 1,012,720 | 742,075 |
| Risk adjustment payable | (14,311) | (1,652,744) | — | — |
| Accounts payable and other liabilities | (3,941) | (149,325) | 2,696 | 192,611 |
| Unearned revenue | 79 | (10,614) | (42,760) | 14,902 |
| Warrant liability | 16,924 | — | — | — |
| Risk share payable to deconsolidated entity | 0 | 123,981 | — | — |
| Net cash used in operating activities | (123,217) | (2,726,546) | 234,466 | 82,059 |
| Cash flows from investing activities: | ||||
| Purchases of investments | (14,963) | (837,074) | (1,457,444) | (1,017,588) |
| Proceeds from sales, paydowns, and maturities of investments | 7,069 | 1,960,283 | 1,055,479 | 926,901 |
| Purchases of property and equipment | (2,333) | (2,897) | (27,448) | (30,414) |
| Proceeds from sale of business, net | 197,121 | (682) | — | — |
| Business acquisitions, net of cash acquired | — | 0 | (310) | (431,791) |
| Net cash provided by investing activities | 186,894 | 1,119,630 | (429,723) | (552,892) |
| Cash flows from financing activities: | ||||
| Proceeds from issuance of preferred stock | — | 0 | 920,417 | 0 |
| Proceeds from issuance of common stock | — | 0 | 1,315 | 11,390 |
| Proceeds from long-term borrowings | 119,804 | 66,400 | — | — |
| Proceeds from short-term borrowings | 2,000 | 0 | 303,947 | 355,000 |
| Repayments of short-term borrowings | (273,636) | 0 | (155,000) | (200,000) |
| Payments for debt issuance costs | — | — | 0 | (3,391) |
| Purchase of non-controlling interests | (93,950) | — | — | — |
| Distribution to non-controlling interest holders | (7,770) | (16,494) | (4,311) | — |
| Proceeds from IPO | — | — | 0 | 887,328 |
| Payments for IPO offering costs | — | — | 0 | (6,686) |
| Net cash (used in) provided by financing activities | (253,552) | 49,906 | 1,066,368 | 1,043,641 |
| Net decrease in cash and cash equivalents | (189,875) | (1,557,010) | 871,111 | 572,808 |
| Cash and cash equivalents of continuing and discontinued operations– beginning of year | 375,280 | 1,932,290 | 1,061,179 | 488,371 |
| Cash and cash equivalents of continuing and discontinued operations– end of year | 185,405 | 375,280 | — | 1,061,179 |
| Supplemental disclosures of cash flow information: | ||||
| Issuance of equity warrants | 1,157 | — | — | — |
| Changes in unrealized gain (loss) on available-for-sale securities in OCI | 122 | 4,307 | (1,094) | (5,761) |
| Cash paid for interest | — | 36,166 | 10,303 | 4,592 |
| Redeemable convertible preferred stock issued for acquisitions | — | — | 0 | 134,944 |
| Contingent consideration | — | — | 332 | (4,221) |
| Conversion of redeemable convertible preferred stock to common stock upon initial public offering | — | — | 0 | 1,815,916 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.